Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics rese...
Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease
About this item
Full title
Author / Creator
Publisher
United States: John Wiley and Sons Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley and Sons Inc
Subjects
More information
Scope and Contents
Contents
Biological and clinical heterogeneity is a major challenge in research for developing new treatments for Alzheimer's disease (AD). AD may be defined by its amyloid beta and tau pathologies, but we recognize that mixed pathologies are common, and that diverse genetics, central nervous system (CNS) and systemic pathophysiological processes, and envir...
Alternative Titles
Full title
Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11485305
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11485305
Other Identifiers
ISSN
1552-5260,1552-5279
E-ISSN
1552-5279
DOI
10.1002/alz.14063
